A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of SB773812 Tablets. - Full Text View

Sponsored by:	GlaxoSmithKline
Information provided by:	GlaxoSmithKline
ClinicalTrials.gov Identifier:	NCT00500201

Purpose

Study to compare PK of a new 120mg tablet with two 60mg tablets. This is required because we plan to have only single tablets administered in the later phase clinical trials but we have not had a 120mg strength before. As this is a new previously untested strength we need to ensure that the PK is similar to that achieved using 2x60mg before we start a large manufacturing campaign and before we administer to a large number of patients. The study is planned to consist of a single part, with two dosing periods, periods 1 and 2 consisting of 18 subjects. There will be 20 days washout between each dose. Initially 4 subjects will be given a single oral dose of 120 mg SB-773812 and 2 will be given placebo. If 120mg SB-773812 is well tolerated in the first four volunteers, the remaining 12 subjects will be dosed. If the 120mg single oral dose in the first 4 subjects is poorly tolerated, the study will be stopped. Subjects will return to the centre for follow-up 14 to 21 days after the final dose.It is expected that the total duration of the study should be approximately 11 weeks.

Condition	Intervention	Phase
Schizophrenia	Drug: SB- 773812	Phase I

MedlinePlus related topics: Schizophrenia

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind, Crossover Assignment, Bio-availability Study
Official Title:	A Single Blind, Double Dummy, Placebo Controlled, Randomized, 2 Period Crossover Study to Assess the Relative Bioavailability of a 120mg Tablet Compared to Two 60 mg SB-773812 Tablets in Healthy Volunteers

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:

Blood sampling over a period 336 hrs post SB773812 dosing in both dosing sessions. [ Time Frame: 336 hrs post SB773812 dosing ]

Secondary Outcome Measures:

Safety: ECG, vital signs, clinical labs over 336 hours post SB-773812 dosing in both dosing sessions. [ Time Frame: 336 hours post SB-773812 dosing ]
Continuous adverse event monitoring from dosing until study conclusion and follow up, 7-14days after last dose. [ Time Frame: 7-14days after last dose ]

Enrollment:	18
Study Start Date:	May 2007

Eligibility

Ages Eligible for Study:	18 Years to 55 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

be a healthy man or woman, aged 18 to 55, and be neither too fat nor too thin;
If you are a woman who can have a baby, you must use an acceptable method of contraception, from the start of your last period before you take the study medicine, until you've had your first normal period after the end of the study. You might need to use contraception for longer than that. You don't need to use contraception if your partner has been sterilized (had an operation to cut the tubes that carry sperm).
Acceptable methods of contraception for women are:
Diaphragm or cap and condom with spermicide;
the 'Pill' and condom with spermicide — you must have been taking the 'Pill' for at least 3 months before the start of the study;
Intrauterine device (IUD or 'coil' — your GP must confirm that you have one) and condom with spermicide; or
Condom and spermicide only, if you're a woman who has had an operation to have your tubes tied.
If you are a woman who CANNOT have a baby, you should have gone through menopause at least 1 year ago;
had your womb removed; or
had both ovaries removed.
have normal physical exam
have normal blood pressure and pulse.
be able to swallow tablets;
show proof of identity — we'll tell you what's suitable.
have the ability to understand and comply with protocol requirements, instructions and restrictions.
be available to attend the ward for repeat tests, if necessary, during the 2 weeks after your final planned visit.

Exclusion Criteria:

abuse alcohol or drugs;
drink, on average, more than 3 units of alcohol daily if you're a man, or 2 units if you're a woman (1 unit = ½ pint of beer, 1 small glass of wine or 1 measure of spirits);
have been a blood donor in the last 3 months;
have been given an experimental medicine in the last 3 months;
have taken part in a study of an experimental medicine in the last 3 months;
be a smoker, or have smoked cigarettes or used other tobacco products regularly in the last 6 months — we may test your breath for smoking at any time during the study;
be pregnant or breast feeding;
have had a serious reaction to any medicine;
have any screening test results that show you're not suitable, even if they don't mean that you're unhealthy;
have had any important illness (including diabetes and asthma) that, in the opinion of the study doctor, makes you unsuitable for the study;
have had any mental illnesses;
suffer from numbness or tingling in your arms, legs, hands or feet; or
has had glaucoma (increased pressure inside the eye).
You may not be able to take part if you've taken any medicines recently, including herbal remedies like St John's wort.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00500201

Locations

United Kingdom
GSK Investigational Site
London, United Kingdom, NW10 7NS

Sponsors and Collaborators

GlaxoSmithKline

Investigators

Study Director:

GSK Clinical Trials, MBChB MFPM

GlaxoSmithKline

More Information

Responsible Party:	GSK ( Study Director )
Study ID Numbers:	NAA105737
Study First Received:	July 10, 2007
Last Updated:	October 9, 2008
ClinicalTrials.gov Identifier:	NCT00500201
Health Authority:	United Kingdom: Research Ethics Committee

Keywords provided by GlaxoSmithKline:

Healthy Volunteer

Study placed in the following topic categories:

Schizophrenia
Mental Disorders
Psychotic Disorders
Healthy
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on January 14, 2009